Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat liver diseases. The company's lead product is Ocaliva, which is used for the treatment of primary biliary cholangitis.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Intercept Pharmaceuticals has announced a restructuring that will result in 146 layoffs, following the withdrawal of its drug Ocaliva. This decision comes as the company seeks to realign its operations after the setback with Ocaliva, which has impacted its business strategy. The layoffs are part of a broader effort to streamline the organization and focus on future growth opportunities. The exact locations and departments affected by these layoffs have not been disclosed. This move reflects the challenges faced by Intercept in the current pharmaceutical landscape.
Intercept Pharmaceuticals has laid off 146 employees following safety concerns related to one of its drugs, which was linked to several deaths. The layoffs are part of a broader response to the challenges the company faces in ensuring drug safety and maintaining operational efficiency. This decision reflects the company's commitment to addressing these serious issues while navigating the complexities of the pharmaceutical industry. The layoffs took effect in early October 2023, impacting the workforce in New Jersey.
No one has shared a story from Intercept yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.